Health Care & Life Sciences » Biotechnology | Regulus Therapeutics Inc.

Regulus Therapeutics Inc. | Ownership

Companies that own Regulus Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BVF Partners LP
13,685,204
13.06%
-289,045
0.21%
06/30/2018
Fidelity Management & Research Co.
8,537,762
8.15%
-7,110,170
0%
07/31/2018
The Vanguard Group, Inc.
2,637,904
2.52%
-129,261
0%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
1,697,802
1.62%
0
0.03%
06/30/2018
South Dakota Investment Council
1,683,601
1.61%
-93,126
0.01%
06/30/2018
Ascend Capital LLC
1,092,553
1.04%
78,936
0.01%
06/30/2018
Point72 Asset Management LP
737,995
0.7%
0
0%
06/30/2018
BlackRock Fund Advisors
585,357
0.56%
-181,430
0%
06/30/2018
New York Life Investment Management LLC
500,000
0.48%
0
0%
06/30/2018
Rhenman & Partners Asset Management AB
492,878
0.47%
0
0.01%
06/30/2018

About Regulus Therapeutics

View Profile
Address
10628 Science Center Drive
San Diego California 92121
United States
Employees -
Website http://www.regulusrx.com
Updated 07/08/2019
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.